JPH0592974A - New process for producing neplanocin a - Google Patents

New process for producing neplanocin a

Info

Publication number
JPH0592974A
JPH0592974A JP2414449A JP41444990A JPH0592974A JP H0592974 A JPH0592974 A JP H0592974A JP 2414449 A JP2414449 A JP 2414449A JP 41444990 A JP41444990 A JP 41444990A JP H0592974 A JPH0592974 A JP H0592974A
Authority
JP
Japan
Prior art keywords
compound
group
formula
amino
neplanocin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2414449A
Other languages
Japanese (ja)
Inventor
Masaji Ono
雅二 大野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd filed Critical Asahi Chemical Industry Co Ltd
Priority to JP2414449A priority Critical patent/JPH0592974A/en
Publication of JPH0592974A publication Critical patent/JPH0592974A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

PURPOSE:To chemically synthesize the subject compound by reacting a cyclopentene compound with an aminodihalopyrimidine, subjecting the obtained pyrimidine compound to imidazole cyclization reaction, converting the halogen group of the produced purine compound to amino group and deprotecting the product. CONSTITUTION:The objective compound is produced by reacting a cyclopentene compound of formula I (R'2 to R'4 are OH-protecting group) with a 5-amino-4,6- dihalopyrimidine, subjecting the resultant pyrimidine compound of formula II (X is halogen) to imidazole cyclization reaction to obtain a purine compound of formula III, converting the 6-halogeno group of the compound to amino group and eliminating the protecting groups of the 2'-, 3'- and 6-hydroxyl groups.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、ネプラノシンAの新規
な製造法に関する。
FIELD OF THE INVENTION The present invention relates to a novel method for producing neplanocin A.

【0002】[0002]

【従来の技術】ネプラノシンA(Neplanocin
A)(抗生物質A11079−B1bと呼称した)は、
シクロペンテン環をもつ核酸関連物質であって、式
2. Description of the Related Art Neplanocin A (Neplanocin)
A) (designated antibiotic A11079-B 1b )
A nucleic acid-related substance having a cyclopentene ring, which has the formula:

【化4】 で示され〔カレント ケモセラピー アンド インフエ
クションズ ディシーズ(Current Chemo
therapy and InfectionsDis
ease,1558〜1559(1980)〕、1’
(R)、2’(S)、3’(R)の絶対配置をもつこと
が確認されており、ヌクレイック アシドリサーチ シ
ンポジュウム シリーズ〔Nucleic acids
Research Symposium Serie
s No.8、S65〜S67(1980)〕、植物病
原菌糸状菌生育阻害作用およびマウス白血病L1210
細胞生育阻害作用を有するだけでなく、エールリッヒ腹
水癌、ザルコーマ180、P388白血病、ラットの吉
田肉腫に対しても著しい延命効果を示し、制癌剤として
有用な抗生物質である。従来、ネプラノシンAは、アン
プラリエーラ・スピーシーズ(Ampullariel
la sp.)A11079(FERM−P4494)
の培養物から採取する醗酵法(特開昭54−15479
2号)により得られていた。
[Chemical 4] Indicated by [Current Chemotherapy and Influences Diseases (Current Chemo
therapy and InfectionsDis
ease, 1558 to 1559 (1980)], 1 '
(R), 2 '(S), and 3' (R) have been confirmed to have absolute configurations, and Nucleic Acid Research Symposium series [Nucleic acids
Research Symposium Series
s No. 8, S65-S67 (1980)], plant pathogenic fungal growth inhibitory action and mouse leukemia L1210
Not only it has a cell growth inhibitory action, but also shows a remarkable life-prolonging effect on Ehrlich's ascites cancer, Sarcoma 180, P388 leukemia, and Yoshida's sarcoma of rats, and is a useful anticancer drug. Traditionally, neplanocin A has been used in Ampulariel species.
la sp. ) A11079 (FERM-P4494)
Fermentation method (Japanese Patent Laid-Open No. 54-15479)
No. 2).

【0003】[0003]

【発明が解決しようとする課題】本発明者は、ネプラノ
シンAがその糖部位にシクロペンテン環を有するアデニ
ン誘導体であり、その化学構造および生理活性に興味を
持たれている物質であることから、このネプラノシンA
を全合成するより、醗酵法による製造上の欠点を解消す
ることに着目した。
DISCLOSURE OF THE INVENTION The present inventor has determined that neplanocin A is an adenine derivative having a cyclopentene ring at its sugar moiety and is a substance of interest in its chemical structure and physiological activity. Neplanocin A
Attention was focused on eliminating the drawbacks in the production by the fermentation method, rather than the total synthesis of.

【0004】しかしながら、ネプラノシンAを化学的に
合成するためには、シクロペンテニル部位を天然型と同
一の光学活性な形で合成することが必要である。そこ
で、本発明者は、シクロペンタジエンとアセチレンジカ
ルボン酸ジメチルエステルからなる3段階で得られる式
However, in order to chemically synthesize neplanocin A, it is necessary to synthesize the cyclopentenyl moiety in the same optically active form as the natural form. Therefore, the inventor of the present invention has the formula obtained by three steps consisting of cyclopentadiene and acetylenedicarboxylic acid dimethyl ester.

【化5】 の対称ジエステルを出発原料とし、これを豚肝臓エステ
ラーゼにより不斉選択加水分解して(−)体のモノエス
テルを得、このモノエステルを用いて種々合成研究を続
けた結果、本発明を完成したものである。
[Chemical 5] As a starting material, the symmetric diester of 1. was asymmetrically selectively hydrolyzed by pig liver esterase to obtain a (-)-form monoester, and various synthetic studies were continued using this monoester, and as a result, the present invention was completed. It is a thing.

【0005】[0005]

【課題を解決するための手段】本発明は、式The present invention is based on the formula

【化6】 (式中、R' 2 およびR’3 は各々水酸基の保護基、
R’4 は水酸基の保護基を示す)で表されるシクロペン
テン化合物を5−アミノ−4,6−ジハロピリミジンと
反応させて式
[Chemical 6] (In the formula, R ′ 2 and R ′ 3 are each a hydroxyl-protecting group,
R '4 is a cyclopentene compound represented by a protecting group for hydroxyl group) is reacted with 5-amino-4,6-di-halo pyrimidine formula

【化7】 (式中、Xはハロゲン原子を示し、R’2 、R’3 およ
びR’4 は前記と同じ基を意味する)で表されるピリミ
ジン化合物を得、該化合物をイミダゾール閉環して式
[Chemical 7] (Wherein, X represents a halogen atom, and R ′ 2 , R ′ 3 and R ′ 4 mean the same groups as described above), and the compound is ring-closed with an imidazole compound to give a pyrimidine compound.

【化8】 (式中、R' 2 、R’3 、R’4 およびXは前記と同じ
基を意味する)で表されるプリン化合物を得、該化合物
の6位のハロゲノ基をアミノ基に変換し、次いで2’
位、3’位および6’位の水酸基の保護基を脱離してネ
プラノシンAを製造するものである。
[Chemical 8] (Wherein, R '2, R' 3 , R '4 and X mean the same groups as above) to give purine compound represented by converting the 6-position of the halogeno group of the compound to the amino group, Then 2 '
The nepranocin A is produced by removing the protective groups of the hydroxyl groups at the 3'-position and the 6'-position.

【0006】上記の出発物質〔Ic〕を製造するには、
シクロペンタジエンとアセチレンジカルボン酸ジエステ
ル、例えばジメチルエステルからDiels−Alde
r反応により得たビシクロ〔2.2.1〕−ヘプタ−
2,5−ジエン−2,3−ジカルボン酸ジエステル、例
えばジメチルエステルをOsO4 酸化し、得られた5,
6−ジヒドロキシ−ビシクロ〔2.2.1〕−ヘプタ−
2−エン−2,3−ジカルボン酸ジエステルのジヒドロ
キシ基を適当な保護基、例えばイソプロピリデン基で保
護し、得られた5,6−O−保護−5,6−ジヒドロキ
シ−ビシクロ〔2.2.1〕−ヘプタ−2−エン−2,
3−ジカルボン酸ジエステル、例えば5,6−O−イソ
プロピリデン−5,6−ジヒドロキシ−ビシクロ〔2.
2.1〕−ヘプタ−2−エン−2,3−ジカルボン酸ジ
メチルエステル(1)をエステラーゼ、例えばブタ肝臓
エステラーゼで不斉加水分解してモノエステル、例えば
モノメチルエステル(2)を得、これをオゾン酸化して
2,3−O−保護−2,3−ジヒドロキシ−4−アルコ
キシオキサリル−シクロペンタン−1−カルボン酸、例
えば2,3−O−イソプロピリデン−2,3−ジヒドロ
キシ−4−メトキサリル−シクロペンタン−1−カルボ
ン酸(3)を得、これを2,3−O−保護−2,3−ジ
ヒドロキシ−4−ホルミル−シクロペンタン−1−カル
ボン酸、例えば2,3−O−イソプロピリデン−2,3
−ジヒドロキシ−4−ホルミル−シクロペンタン−1−
カルボン酸(4)に変換し、これを2−オキソ−6,7
−O−保護−3−オキサビシクロ〔3.2.1〕オクタ
ン−6,7−ジオール、例えば2−オキソ−6,7−O
−イソプロピリデン−3−オキサビシクロ〔3.2.
1〕オクターン−6,7−ジオール(5)に変換し、こ
れを2,3−O−保護−2,3−ジヒドロキシ−4−フ
エニルセレノメチル−シクロペンタン−1−カルボン
酸、例えば2,3−O−イソプロピリデン−2,3−ジ
ヒドロキシ−4−フエニルセレノメチル−シクロペンタ
ン−1−カルボン酸(6)に変換し、これをクルチウス
反応によりイソシアネート化した後、1−保護アミノ−
2,3−O−保護−4−フエニルセレノ−シクロペンタ
ン−2,3−ジオール、例えば1−メトキシカルボニル
アミノ−2,3−O−イソプロピリデン−4−フエニル
セレノ−シクロペンタン−2,3−ジオール(7)に変
換し、これをエキソメチレン化して1−保護アミノ−
2,3−O−保護−4−メチレンシクロペンタン−2,
3−ジオール、例えば1−メトキシカルボニルアミノ−
2,3−O−イソプロピリデン−4−メチレンシクロペ
ンタン−2,3−ジオール(8)を得、これをエポキシ
化して1−保護アミノ−2,3−O−保護−4−(オキ
シラン−2−イル)−シクロペンタン−2,3−ジオー
ル、例えば1−メトキシカルボニルアミノ−2,3−O
−イソプロピリデン−4−(オキシラン−2−イル)−
シクロペンタン−2,3−ジオール(9)を得、これを
To produce the above-mentioned starting material [Ic],
Cyclopentadiene and acetylenedicarboxylic acid diesters such as dimethyl ester from Diels-Alde
Bicyclo [2.2.1] -hepta obtained by r reaction
5,5-diene-2,3-dicarboxylic acid diester, for example dimethyl ester, was obtained by oxidation with OsO 4 ,
6-dihydroxy-bicyclo [2.2.1] -hepta-
The dihydroxy group of the 2-ene-2,3-dicarboxylic acid diester is protected with a suitable protecting group such as an isopropylidene group, and the resulting 5,6-O-protected-5,6-dihydroxy-bicyclo [2.2] is obtained. .1] -Hepta-2-ene-2,
3-dicarboxylic acid diesters such as 5,6-O-isopropylidene-5,6-dihydroxy-bicyclo [2.
2.1] -Hepta-2-ene-2,3-dicarboxylic acid dimethyl ester (1) is asymmetrically hydrolyzed with an esterase such as pig liver esterase to obtain a monoester such as monomethyl ester (2). Ozone-oxidized to 2,3-O-protected-2,3-dihydroxy-4-alkoxyoxalyl-cyclopentane-1-carboxylic acid, eg 2,3-O-isopropylidene-2,3-dihydroxy-4-methoxaryl -Cyclopentane-1-carboxylic acid (3) is obtained, which is 2,3-O-protected-2,3-dihydroxy-4-formyl-cyclopentane-1-carboxylic acid, such as 2,3-O-isopropyloxy. Reden-2,3
-Dihydroxy-4-formyl-cyclopentane-1-
Converted to carboxylic acid (4), which was treated with 2-oxo-6,7
-O-protected-3-oxabicyclo [3.2.1] octane-6,7-diol, such as 2-oxo-6,7-O.
-Isopropylidene-3-oxabicyclo [3.2.
1] converted to octane-6,7-diol (5), which is 2,3-O-protected-2,3-dihydroxy-4-phenylselenomethyl-cyclopentane-1-carboxylic acid, for example 2, After conversion to 3-O-isopropylidene-2,3-dihydroxy-4-phenylselenomethyl-cyclopentane-1-carboxylic acid (6), which was isocyanated by the Curtius reaction, 1-protected amino-
2,3-O-protected-4-phenylseleno-cyclopentane-2,3-diol, such as 1-methoxycarbonylamino-2,3-O-isopropylidene-4-phenylseleno-cyclopentane-2,3-diol ( 7) and converted to exomethylene to 1-protected amino-
2,3-O-protected-4-methylenecyclopentane-2,
3-diol, for example 1-methoxycarbonylamino-
2,3-O-isopropylidene-4-methylenecyclopentane-2,3-diol (8) was obtained, which was epoxidized to give 1-protected amino-2,3-O-protected-4- (oxirane-2). -Yl) -cyclopentane-2,3-diol, for example 1-methoxycarbonylamino-2,3-O
-Isopropylidene-4- (oxiran-2-yl)-
Cyclopentane-2,3-diol (9) is obtained, which has the formula

【化9】 (式9中、R’1 はアミノ基の保護基、R’2 および
R’3 は前記と同じ基を意味する)で表される1−保護
アミノ−2,3−O−保護−4−ヒドロキシメチル−4
−シクロペンテン−2,3−ジオール、例えば1−メト
キシカルボニルアミノ−2,3−O−イソプロピリデン
−4−ヒドロキシメチル−4−シクロペンテン−2,3
−ジオール(10)に変換し、この6’位の水酸基を前
述の保護基で保護して式
[Chemical 9] (In formula 9, R ′ 1 represents an amino-group protecting group, and R ′ 2 and R ′ 3 represent the same groups as described above.) 1-protected amino-2,3-O-protected-4- Hydroxymethyl-4
-Cyclopentene-2,3-diol, for example 1-methoxycarbonylamino-2,3-O-isopropylidene-4-hydroxymethyl-4-cyclopentene-2,3
-Converted to a diol (10) and protecting the 6'-hydroxyl group with the above-mentioned protecting group

【化10】 (式中、R’1 、R’2 、R3 およびR’4 は前記と同
じ基を意味する)で表される1−保護アミノ−2,3−
O−保護−4−保護−ヒドロキシメチル−4−シクロペ
ンテン−2,3−ジオール、例えば1−メトキシカルボ
ニルアミノ−2,3−O−イソプロピリデン−4−メト
キシメトキシメチル−4−シクロペンテン−2,3−ジ
オール(11)を得、このアミノ保護基を脱離すること
により式〔Ic〕で表されるシクロペンテン化合物、例
えば1−アミノ−2,3−O−イソプロピリデン−4−
メトキシメトキシメチル−4−シクロペンテン−2,3
−ジオール(12)が得られる。
[Chemical 10] (In the formula, R ′ 1 , R ′ 2 , R 3 and R ′ 4 represent the same groups as described above) 1-protected amino-2,3-
O-protected-4-protected-hydroxymethyl-4-cyclopentene-2,3-diol, such as 1-methoxycarbonylamino-2,3-O-isopropylidene-4-methoxymethoxymethyl-4-cyclopentene-2,3. A cyclopentene compound represented by the formula [Ic], for example, 1-amino-2,3-O-isopropylidene-4-, by obtaining a diol (11) and removing the amino protecting group.
Methoxymethoxymethyl-4-cyclopentene-2,3
A diol (12) is obtained.

【0007】上記の式〔Ia〕および〔Ib〕のアミノ
基の保護基としては、アミノ基を保護する公知の保護基
であって、例えばホルミル基、トリフルオロアセチル
基、クロロアセチル基、o−ニトロフエノキシアセチル
基、フタロイル基、p−トルエンスルホニル基、o−ニ
トロフエニルスルフエニル基などのアシル基、ベンジル
オキシカルボニル基、o(またはp)−ブロモベンジル
オキシカルボニル基、o(またはp)−クロロベンジル
オキシカルボニル基、p−ニトロベンジルオキシカルボ
ニル基、p−メトキシベンジルオキシカルボニル基、p
−フエニルアゾベンジルオキシカルボニル基、p−
(p’−メトキシフエニルアゾ)ベンジルオキシカルボ
ニル基などのベンジルオキシカルボニル基、トリクロロ
エトキシカルボニル基、メトキシカルボニル基、t−ブ
トキシカルボニル基、t−アミルオキシカルボニル基、
ジイソプロピルメトキシカルボニル基などの脂肪族オキ
シカルボニル基、2−フエニル−イソプロキシカルボニ
ル基、2−トリル−イソプロポキシカルボニル基などの
アラルキルオキシカルボニル基、トリメチルシリルなど
のシリル基などが挙げられる。またこのアミノ基をベン
ゾイルアセトン、アセチルアセトンなどの1,3−ジケ
トンと反応させることによって得られるエナミンの形成
による保護基も挙げられる。
The protecting group for the amino group of the above formulas [Ia] and [Ib] is a known protecting group for protecting the amino group, and examples thereof include formyl group, trifluoroacetyl group, chloroacetyl group and o-. Acyl group such as nitrophenoxyacetyl group, phthaloyl group, p-toluenesulfonyl group, o-nitrophenylsulfenyl group, benzyloxycarbonyl group, o (or p) -bromobenzyloxycarbonyl group, o (or p ) -Chlorobenzyloxycarbonyl group, p-nitrobenzyloxycarbonyl group, p-methoxybenzyloxycarbonyl group, p
-Phenylazobenzyloxycarbonyl group, p-
Benzyloxycarbonyl group such as (p′-methoxyphenylazo) benzyloxycarbonyl group, trichloroethoxycarbonyl group, methoxycarbonyl group, t-butoxycarbonyl group, t-amyloxycarbonyl group,
Examples thereof include an aliphatic oxycarbonyl group such as a diisopropylmethoxycarbonyl group, an aralkyloxycarbonyl group such as a 2-phenyl-isoproxycarbonyl group, a 2-tolyl-isopropoxycarbonyl group, a silyl group such as trimethylsilyl, and the like. Further, a protecting group by the formation of an enamine obtained by reacting this amino group with a 1,3-diketone such as benzoylacetone or acetylacetone is also included.

【0008】上記式〔Ia〕、〔Ib〕および〔Ic〕
の2’位、3’位および6’位の水酸基の保護基として
は、核酸化学または炭水化物化学において使用される公
知の保護基が挙げられる。6’位の水酸基の保護基とし
ては、例えばホルミル、アセチル、クロロアセチル、ト
リクロロアセチル、トリフルオロアセチル、メトキシア
セチル、ピバロイル、ベンゾイル、β−ベンゾイルプロ
ピオニル、フエノキシアセチル、トリチルオキシアセチ
ルなどのアシル基、トリチル、モノメトキシトリチル、
ジメトキシトリチル、トリメトキシトリチルなどのトリ
チル基、メトキシメチル基などが挙げられる。2’位お
よび3’位の水酸基の保護基としては、ホルミル、アセ
チル、メトキシアセチル、ベンゾイル、p−クロロベン
ジルオキシアセチルなどのアシル基、t−ブチル、ベン
ジル、トリチル、α−エトキシエチル、α−メトキシイ
ソプロピル、テトラヒドロピラニル、メトキシテトラヒ
ドロピラニル、o−ニトロベンジル、t−ブチルジフエ
ニルシリル基などが挙げられる。また2’位および3’
位の水酸基は隣接する酸素原子と共に環状アセタールを
形成する形で保護される。このような保護基としては、
イソプロピリデン、メトキシメチレン、メトキシエチリ
デン、エトキシメチレン、エトキシエチリデン、ベンジ
リデン、シクロアルキリデン基などが挙げられる。
The above formulas [Ia], [Ib] and [Ic]
Examples of the protective group for the hydroxyl groups at the 2′-position, 3′-position and 6′-position include known protecting groups used in nucleic acid chemistry or carbohydrate chemistry. Examples of the 6'-hydroxyl protecting group include an acyl group such as formyl, acetyl, chloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, pivaloyl, benzoyl, β-benzoylpropionyl, phenoxyacetyl, and trityloxyacetyl. , Trityl, monomethoxytrityl,
Examples thereof include a trityl group such as dimethoxytrityl and trimethoxytrityl, a methoxymethyl group and the like. Examples of the protective group for the hydroxyl groups at the 2'-position and the 3'-position include an acyl group such as formyl, acetyl, methoxyacetyl, benzoyl, p-chlorobenzyloxyacetyl, t-butyl, benzyl, trityl, α-ethoxyethyl, α-. Methoxyisopropyl, tetrahydropyranyl, methoxytetrahydropyranyl, o-nitrobenzyl, t-butyldiphenylsilyl group and the like can be mentioned. Also 2'and 3 '
The hydroxyl group at the position is protected by forming a cyclic acetal together with the adjacent oxygen atom. Such protecting groups include:
Examples include isopropylidene, methoxymethylene, methoxyethylidene, ethoxymethylene, ethoxyethylidene, benzylidene, and cycloalkylidene groups.

【0009】次に、中間体〔Ic〕の合成の一例とし
て、2’位および3’位の水酸基がイソプロピリデン基
で保護され、6’位の水酸基がメトキシメチル基で保護
され、1’位のアミノ基がメトキシカルボニル基で保護
される場合について、反応式で示せば、次の通りであ
る。
Next, as an example of the synthesis of the intermediate [Ic], the hydroxyl groups at the 2'position and the 3'position are protected with an isopropylidene group, the hydroxyl group at the 6'position is protected with a methoxymethyl group, and the 1'position. The case where the amino group of is protected by a methoxycarbonyl group is shown below by a reaction formula.

【化11】 [Chemical 11]

【化12】 [Chemical formula 12]

【化13】 前記の中間体〔Ia〕、中間体〔Ib〕、中間体〔I
c〕としては、上記の如く具体的に例挙した化合物以外
に、2’および3’位の水酸基、6’位の水酸基または
1’位のアミノ基を前記で述べた保護基を導入した誘導
体についても例示される。本発明においては、上記の中
間体は光学活性の形で得られ、特に(−)−異性体が有
用である。
[Chemical 13] The above intermediate [Ia], intermediate [Ib], intermediate [I
c] is, in addition to the compounds specifically exemplified above, a derivative in which a hydroxyl group at the 2 ′ and 3 ′ positions, a hydroxyl group at the 6 ′ position or an amino group at the 1 ′ position is introduced with the above-mentioned protecting groups. Is also illustrated. In the present invention, the above-mentioned intermediate is obtained in an optically active form, and the (-)-isomer is particularly useful.

【0010】シクロペンテン化合物〔Ic〕と5−アミ
ノ−4,6−ジハロピリミジンとの反応は、通常有機溶
媒中第3級有機アミンの存在下加熱下で行われる。反応
の経過はシリカゲルなどの薄層クロマトグラフイー(T
LC)、高速液体クロマトグラフイー(HPLC)など
により確認できるので、出発物質〔Ic〕の消失を待っ
て適宜反応を停止すればよい。反応液から得られたピリ
ミジン化合物〔II〕を採取するには、反応溶媒を留去
し、適当な有機溶媒で抽出すればよい。さらに精製を必
要とする場合には、シリカゲルなどの担体を用いるカラ
ムクロマトグラフイーなどにより精製することができ
る。
The reaction between the cyclopentene compound [Ic] and 5-amino-4,6-dihalopyrimidine is usually carried out in an organic solvent in the presence of a tertiary organic amine under heating. The progress of the reaction is shown by thin layer chromatography (T
Since it can be confirmed by LC), high performance liquid chromatography (HPLC), etc., the reaction may be appropriately stopped after the disappearance of the starting material [Ic]. In order to collect the pyrimidine compound [II] obtained from the reaction solution, the reaction solvent may be distilled off and extraction with a suitable organic solvent may be performed. When further purification is required, it can be purified by column chromatography using a carrier such as silica gel.

【0011】次に、ピリミジン化合物〔II〕をイミダ
ゾール閉環するのであるが、4,5−ジアミノピリミジ
ン類をプリン類に閉環する公知の方法、例えばギ酸、ギ
酸アルカリ、ホルムアミド、クロルギ酸エステル、トリ
エチルオルソホルメート、N−ホルミル−ホルモリンな
どと加熱閉環する方法、ジチオギ酸アリカリで処理し、
次いで脱硫化水素化する方法により行われる。
Then, the pyrimidine compound [II] is subjected to imidazole ring closure by a known method for ring closure of 4,5-diaminopyrimidines into purines, for example, formic acid, alkali formate, formamide, chloroformate, triethylortho. A method of ring closure by heating with formate, N-formyl-formolin, etc., treatment with potassium alithioformate,
Then, it is carried out by the method of desulfurization.

【0012】このようにして得られたプリン化合物〔I
II〕の6位のハロゲノ基をアミノ基に変換するのであ
るが、通常は有機溶媒中アンモニア処理することにより
行われる。反応液から生成された式
The purine compound [I obtained in this way
The halogeno group at the 6-position of II] is converted to an amino group, which is usually carried out by treating with ammonia in an organic solvent. Formula generated from reaction solution

【化14】 (式中、R’2 、R’3 およびR’4 は前記と同じ基を
意味する)で表されるO−保護ネプラノシンAを採取す
るには、反応溶媒を留去し、適当な有機溶媒で抽出すれ
ばよい。さらに精製を必要とする場合には、シリカゲル
などの担体を用いてカラムクロマトグラフイーなどによ
り精製することができる。
[Chemical 14] (Wherein R ′ 2 , R ′ 3 and R ′ 4 have the same meanings as described above), the O-protected neplanocin A can be collected by distilling the reaction solvent and using a suitable organic solvent. You can extract with. When further purification is required, it can be purified by column chromatography using a carrier such as silica gel.

【0013】次に、O−保護ネプラノシンA〔IV〕の
2’位、3’位および6’位の保護基を脱離することに
よりネプラノシンAが得られるが、この脱離化は、核酸
化学において用いられる公知の脱離方法により行われ
る。例えば、2’、3’−O−イソプロピリデン基およ
び6−O−メトキシメチル基はアルコール、例えばメタ
ノール中塩酸で処理することにより容易に脱離される。
Next, the protecting groups at the 2'-position, 3'-position and 6'-position of O-protected neplanocin A [IV] are removed to obtain neplanocin A, which is eliminated by nucleic acid chemistry. The known desorption method used in. For example, the 2 ', 3'-O-isopropylidene group and the 6-O-methoxymethyl group are easily eliminated by treatment with alcohol, such as hydrochloric acid in methanol.

【0014】このようにして得られたネプラノシンAは
公知の方法により分離精製される。例えば活性炭、活性
アルミナ、シリカゲル、吸着樹脂などの吸着剤に吸着さ
せ、適当な溶媒、例えば含水有機溶媒、弱アルカリ水溶
液で溶出するカラムクロマトグラフイー、アンバーライ
トIRC−50、IR−120、CG−120、ダウエ
ツクス50などのカチオン交換樹脂に吸着させ、弱アル
カリで溶出する方法、あるいはこれらの組合せによる方
法などにより行われる。
The thus-obtained neplanocin A is separated and purified by a known method. For example, column chromatography, Amberlite IRC-50, IR-120, CG-, which is adsorbed on an adsorbent such as activated carbon, activated alumina, silica gel, or an adsorption resin, and eluted with a suitable solvent such as a water-containing organic solvent or a weak alkaline aqueous solution. It is carried out by a method of adsorbing it on a cation exchange resin such as 120 or Dowex 50 and eluting with a weak alkali, or a method of combining these.

【0015】次に出発物質〔Ic〕からネプラノシンA
を製造する代表例を反応式で示せば次の通りである。
Next, from the starting material [Ic] to neplanocin A
The following is a typical example of the production of

【化15】 [Chemical 15]

【化16】 [Chemical 16]

【0016】[0016]

【実施例】次に、参考例および実施例を挙げて本発明の
製造例を具体的に説明するが、これにより本発明を限定
するものでなない。なお、実施例において、( )内の
数字で表示した化合物は、前記反応式で示された数字を
意味する。 参考例 1 化合物(2)の製造 化合物(1)3g(10.6mM)をアセトン30mlと
0.1Mリン酸緩衝液(pH8.0)の混合溶液に溶か
し、これに豚肝臓エステラーゼ(シグマ社製)3mlを加
え、30〜32℃で5時間攪拌した。反応液を氷冷下希
リン酸でpH4とし、ジクロロメタンで数回抽出した。
ジクロロメタン層を水洗し、芒硝で乾燥後、減圧濃縮し
て化合物(2)2.84g(収率99.6%)を得た。 〔α〕23D−23.8°(C=1.17、クロロホル
ム) 融点:115〜11℃
EXAMPLES Next, the production examples of the present invention will be specifically described with reference to Reference Examples and Examples, but the present invention is not limited thereby. In the examples, the compound represented by the number in parentheses means the number shown in the above reaction formula. Reference Example 1 Production of Compound (2) 3 g (10.6 mM) of Compound (1) was dissolved in a mixed solution of 30 ml of acetone and 0.1 M phosphate buffer (pH 8.0), and pig liver esterase (manufactured by Sigma) was dissolved in the solution. ) 3 ml was added and the mixture was stirred at 30 to 32 ° C. for 5 hours. The reaction solution was adjusted to pH 4 with dilute phosphoric acid under ice cooling, and extracted several times with dichloromethane.
The dichloromethane layer was washed with water, dried over Glauber's salt, and concentrated under reduced pressure to obtain 2.84 g of compound (2) (yield 99.6%). [Α] 23 D-23.8 ° (C = 1.17, chloroform) Melting point: 115-11 ° C.

【0017】参考例 2 化合物(3)の製造 化合物(2)2g(7.46mM)を酢酸エチル10ml
に溶かし、これに−78℃に冷却下オゾンを3時間吹き
込んだ。次いで過剰のオゾンを窒素ガスを通して追い出
した後、1時間還流した。反応後、減圧濃縮して化合物
(3)を定量的に得た。
Reference Example 2 Production of Compound (3) 2 g (7.46 mM) of Compound (2) was added to 10 ml of ethyl acetate.
And was blown with ozone for 3 hours while cooling to −78 ° C. Then, excess ozone was purged through nitrogen gas and then refluxed for 1 hour. After the reaction, the mixture was concentrated under reduced pressure to quantitatively obtain the compound (3).

【0018】参考例 3 化合物(4)の製造 化合物(3)1.8g(6.6mM)をメタノール30
mlに溶かし、40〜50℃に加温下NaBH4 2.3g
(66mM)を少しづつ加えた。全量を加えた後、15
分間還流した。反応液を氷水で冷却下希塩酸でpH4に
調節し、室温で攪拌下NaIO4 1.6g(1.2倍モ
ル)を徐々に加え、30分間攪拌した。反応液を希リン
酸で酸性とした後、水を加えジクロロメタンで3回抽出
した。ジクロロメタン層を芒硝で乾燥後、減圧濃縮して
化合物(4)1.25g(収率88%)を得た。
Reference Example 3 Production of Compound (4) 1.8 g (6.6 mM) of Compound (3) was added to methanol 30
Dissolve it in ml and heat NaBH 4 at 40-50 ° C 2.3 g
(66 mM) was added in small portions. 15 after adding the whole amount
Reflux for minutes. The reaction liquid was adjusted to pH 4 with dilute hydrochloric acid while being cooled with ice water, 1.6 g (1.2 times mol) of NaIO 4 was gradually added with stirring at room temperature, and the mixture was stirred for 30 minutes. The reaction solution was made acidic with diluted phosphoric acid, water was added, and the mixture was extracted 3 times with dichloromethane. The dichloromethane layer was dried over sodium sulfate and concentrated under reduced pressure to obtain 1.25 g (yield 88%) of compound (4).

【0019】参考例 4 化合物(5)の製造 化合物(4)1.25g(5.83mM)をイソプロパ
ノール20mlに溶かし、室温で攪拌下NaBH4 431
mg(2倍モル)を少しづつ加えた後、1.5時間攪拌し
た。反応液に氷水で冷却下アセトンを加え、過剰のNa
BH4 を分解した後、酢酸でpH5に調節した。減圧下
溶媒留去し、残渣にエタノールを加え、減圧濃縮し、乾
燥した。残渣に無水酢酸5ml、ピリジン10mlを加え、
室温で12時間攪拌した。反応液を氷水中に注ぎ、ベン
ゼンで抽出した。ベンゼン層を重曹水、希塩酸、水の順
で洗浄し、芒硝で乾燥した後、減圧濃縮した。残渣をシ
リカゲルカラムクロマトグラフイー(展開溶媒ジクロロ
メタン)により精製して化合物(5)700mg(収率6
0.5%)を得た。 〔α〕25D+35.9°(C=0.8、クロロホルム) ジクロロメタン−ジエチルエーテル(1:5)より再結
晶化した再結晶は〔α〕25D+44.4(C=1.0、
クロロホルム)
Reference Example 4 Production of Compound (5) 1.25 g (5.83 mM) of Compound (4) was dissolved in 20 ml of isopropanol, and NaBH 4 431 was stirred at room temperature.
After adding mg (2 times mol) little by little, it stirred for 1.5 hours. Acetone was added to the reaction solution while cooling with ice water, and excess Na was added.
After decomposing BH 4 , the pH was adjusted to 5 with acetic acid. The solvent was distilled off under reduced pressure, ethanol was added to the residue, and the mixture was concentrated under reduced pressure and dried. 5 ml of acetic anhydride and 10 ml of pyridine were added to the residue,
The mixture was stirred at room temperature for 12 hours. The reaction solution was poured into ice water and extracted with benzene. The benzene layer was washed successively with aqueous sodium hydrogen carbonate, dilute hydrochloric acid and water, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (developing solvent dichloromethane) to give compound (5) 700 mg (yield 6
0.5%) was obtained. [Α] 25 D + 35.9 ° (C = 0.8, chloroform) Recrystallization from dichloromethane-diethyl ether (1: 5) gave [α] 25 D + 44.4 (C = 1.0,
Chloroform)

【0020】参考例 5 化合物(6)の製造 ジフエニルジセレナイド173mg(0.56mM)を無
水ジメチルホルムアミド3mlに溶かし、室温にて20分
間窒素ガスを吹き込んだ後、窒素ガス気流下NaBH4
45mg(1.21mM)を徐々に加え、100℃まで加
熱した。次いでこれに化合物(5)201mg(1.01
mM、〔α〕24D+37.3°)のジメチルホルムアミ
ド(2ml)溶液を徐々に滴下した後、110〜120℃
で2時間攪拌した。反応液を氷水で冷却し、希塩酸を含
む氷水中に注ぎ、酢酸エチルで2回抽出した。酢酸エチ
ル層を水洗し、芒硝で乾燥後、減圧濃縮した。残渣をシ
リカゲルカラムクロマトグラフイー(展開溶媒ジクロロ
メタン、次いで、ジクロロメタン:酢酸エチル=2:
1)により精製して化合物(6)335mg(収率93
%)を得た。 〔α〕24D+9.5°(C=1.93、クロロホルム)
Reference Example 5 Preparation of Compound (6) 173 mg (0.56 mM) of diphenyl diselenide was dissolved in 3 ml of anhydrous dimethylformamide, blown with nitrogen gas for 20 minutes at room temperature, and then under a stream of nitrogen gas NaBH 4
45 mg (1.21 mM) was added slowly and heated to 100 ° C. Then, to this, 201 mg of compound (5) (1.01
mM, [α] 24 D + 37.3 °) dimethylformamide (2 ml) solution was slowly added dropwise, and then 110 to 120 ° C.
It was stirred for 2 hours. The reaction solution was cooled with ice water, poured into ice water containing dilute hydrochloric acid, and extracted twice with ethyl acetate. The ethyl acetate layer was washed with water, dried over sodium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (developing solvent dichloromethane, then dichloromethane: ethyl acetate = 2:
Purified by 1), 335 mg of compound (6) (yield 93
%) Was obtained. [Α] 24 D + 9.5 ° (C = 1.93, chloroform)

【0021】参考例 6 化合物(7)の製造 化合物(6)920mg(2.79mM)をアセトン16
mlに溶かし、これにトリエチルアミン0.43ml(1.
8倍モル)を加えた後、攪拌しながら−78〜−40℃
に冷却下クロロ炭酸エチル0.3ml(1.2倍モル)を
適下した。−40℃で30分間攪拌するとトリエチルア
ミン塩酸塩が析出してきた。次いで、これにNaN3
54mg(1.5倍モル)の水(0.5ml)溶液を徐々に
滴下し、−40〜−10℃で30分間攪拌した。IRで
アジドを確認した後、反応液を飽和食塩水を含む氷中に
注ぎ、ジクロロメタンで数回抽出した。ジクロロメタン
層を水洗し、芒硝で乾燥後、減圧濃縮し、乾燥した。次
いで乾燥ベンゼン10mlを加え、30分間還流した。I
Rでイソシアネートをチェックした後、無水メタノール
10mlを加え、1時間還流した。反応液を減圧下溶媒留
去し、残渣をシリカゲルカラムクロマトグラフイー(展
開溶媒ジクロロメタン)により精製して化合物(7)9
06mg(収率91%)を得た。 〔α〕20D+18.8°(C=1.05、クロロホル
ム) 融点:81〜83℃
Reference Example 6 Production of Compound (7) Compound (6) (920 mg, 2.79 mM) was added to acetone 16
Dissolve it in 0.3 ml and add 0.43 ml of triethylamine (1.
(8-fold mole), and then stirred at -78 to -40 ° C.
While cooling, 0.3 ml (1.2 times mol) of ethyl chlorocarbonate was appropriately added. After stirring at -40 ° C for 30 minutes, triethylamine hydrochloride was precipitated. This was followed by NaN 3 2
A solution of 54 mg (1.5 times mol) in water (0.5 ml) was gradually added dropwise, and the mixture was stirred at -40 to -10 ° C for 30 minutes. After confirming the azide by IR, the reaction solution was poured into ice containing saturated saline and extracted several times with dichloromethane. The dichloromethane layer was washed with water, dried over sodium sulfate, concentrated under reduced pressure, and dried. Then 10 ml of dry benzene was added and refluxed for 30 minutes. I
After checking the isocyanate with R, 10 ml of anhydrous methanol was added and the mixture was refluxed for 1 hour. The reaction solution was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (developing solvent dichloromethane) to give compound (7) 9
06 mg (yield 91%) was obtained. [Α] 20 D + 18.8 ° (C = 1.05, chloroform) Melting point: 81 to 83 ° C.

【0022】参考例 7 化合物(8)の製造 化合物(7)167mg(0.435mM)を乾燥ジクロ
ロメタン5mlに溶かし、−78℃に冷却下オゾンを15
分間吹き込んだ。次いで窒素ガスで過剰のオゾンを追い
出し、芒硝で乾燥後、少量のピリジンを加え、2時間還
流した。反応液をシリカゲルカラムクロマトグラフイー
(展開溶媒ジクロロメタン)により精製して化合物
(8)94mg(収率95%)を得た。 〔α〕18D+138.8°(C=1.01、クロロホル
ム)
Reference Example 7 Production of Compound (8) 167 mg (0.435 mM) of Compound (7) was dissolved in 5 ml of dry dichloromethane, and ozone was added thereto under cooling to -78 ° C under 15 ° C.
Blown for a minute. Then, excess ozone was chased with nitrogen gas, dried with Glauber's salt, a small amount of pyridine was added, and the mixture was refluxed for 2 hours. The reaction solution was purified by silica gel column chromatography (developing solvent dichloromethane) to obtain 94 mg (yield 95%) of compound (8). [Α] 18 D + 138.8 ° (C = 1.01, chloroform)

【0023】参考例 8 化合物(9)の製造 化合物(8)46mg(0.21mM)を乾燥ジクロロメ
タン5mlに溶かし、氷冷下m−クロロ過安息香酸57mg
(1.5倍モル)を加え、室温で16時間攪拌した。反
応液を亜硫酸水素ナトリウム水溶液、重曹水の順で洗浄
し、芒硝で乾燥後、減圧下溶媒留去した。得られた油状
物をシリカゲルカラムクロマトグラフイー(展開溶媒ジ
クロロメタン)により精製して化合物(9)45mg(収
率91%)を得た。 〔α〕20D+111.3°(C=1.0、クロロホル
ム) 融点:102〜104℃
Reference Example 8 Preparation of Compound (9) 46 mg (0.21 mM) of Compound (8) was dissolved in 5 ml of dry dichloromethane, and 57 mg of m-chloroperbenzoic acid under ice cooling.
(1.5 times mol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction solution was washed with an aqueous sodium hydrogen sulfite solution and an aqueous sodium hydrogen carbonate solution in that order, dried over sodium sulfate, and then the solvent was distilled off under reduced pressure. The obtained oily substance was purified by silica gel column chromatography (developing solvent dichloromethane) to obtain 45 mg of compound (9) (yield 91%). [Α] 20 D + 111.3 ° (C = 1.0, chloroform) Melting point: 102-104 ° C.

【0024】参考例 9 化合物(10)の製造 乾燥トルエン3mlをアルゴン気流下−78℃に冷却下ト
リメチルシリルトリフルオロメタンスルホネート0.4
5ml(5倍モル)および2,6−ルチジン0.2ml(5
倍モル)を加え、30分間攪拌した。これに化合物
(9)103mg(0.42mM)の乾燥トルエン溶液を
徐々に滴加し、−78℃で30分間、次いで徐々に昇温
して−20℃で3時間攪拌した。次いで、これに1,8
−ジアザビシクロ〔5.4.0〕ウンデンセークーエン
0.3mlを徐々に適加し、室温で16時間攪拌した。反
応混合物を重曹水に注ぎ、酢酸エチルで3回抽出した。
酢酸エチル層を食塩水で洗浄後、減圧下溶媒留去した。
残渣にメタノール2ml、炭酸カリウム270mg(2倍モ
ル)を加え、室温で2時間攪拌して脱シリル化した後、
減圧下溶媒留去した。残渣をジクロロメタンで3〜4回
抽出し、減圧下溶媒留去した。残渣をシリカゲルカラム
クロマトグラフイー(展開溶媒酢酸エチル:ヘキサン=
1:1、次いで酢酸エチル)により精製して原料35mg
(回収率34%)、化合物(10)29mg(収率28
%)を得た。化合物(10)をジエチルエーテル−酢酸
エチルより再結晶化して再結晶品を得た。 〔α〕18D−67.2°(C=0.5、クロロホルム) 融点:139〜140℃
Reference Example 9 Production of Compound (10) 3 ml of dry toluene was cooled to −78 ° C. under a stream of argon and trimethylsilyltrifluoromethanesulfonate 0.4 was added.
5 ml (5 times mole) and 2,6-lutidine 0.2 ml (5
(Double mole) was added and stirred for 30 minutes. To this, a solution of 103 mg (0.42 mM) of compound (9) in dry toluene was gradually added dropwise, and the mixture was stirred at −78 ° C. for 30 minutes and then gradually heated to −20 ° C. for 3 hours. Then 1,8
0.3 ml of diazabicyclo [5.4.0] undensequoene was gradually added, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into aqueous sodium hydrogen carbonate and extracted three times with ethyl acetate.
The ethyl acetate layer was washed with brine and the solvent was evaporated under reduced pressure.
To the residue were added 2 ml of methanol and 270 mg (2 times mol) of potassium carbonate, and the mixture was stirred at room temperature for 2 hours for desilylation.
The solvent was distilled off under reduced pressure. The residue was extracted with dichloromethane 3 to 4 times, and the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (developing solvent ethyl acetate: hexane =
1: 1 then ethyl acetate) and 35 mg starting material
(Recovery rate 34%), Compound (10) 29 mg (yield 28
%) Was obtained. The compound (10) was recrystallized from diethyl ether-ethyl acetate to obtain a recrystallized product. [Α] 18 D-67.2 ° (C = 0.5, chloroform) Melting point: 139 to 140 ° C.

【0025】参考例 10 化合物(11)の製造 化合物(10)84mg(0.345mM)を乾燥ジクロ
ロメタン6mlに溶かし、これにアルゴン気流下エチルジ
イソプロピルアミン89mg(0.69mM)を加え、0
℃に冷却下メトキシメチルクロライド56mg(2倍モ
ル)を滴下し、室温で16時間攪拌した。反応混合物を
氷水中に注ぎ、ジクロロメタン層を重曹水、食塩水の順
で洗浄し、芒硝で乾燥後、減圧下溶媒留去した。残渣を
シリカゲルカラムクロマトグラフイー(展開溶媒酢酸エ
チル:ヘキサン=1:1)により精製して定量的に油状
の化合物(11)99mgを得た。 〔α〕20D−36.2°(C=1.1、クロロホルム)
Reference Example 10 Production of Compound (11) 84 mg (0.345 mM) of Compound (10) was dissolved in 6 ml of dry dichloromethane, and 89 mg (0.69 mM) of ethyldiisopropylamine was added thereto under an argon stream to give 0.
56 mg (2 moles) of methoxymethyl chloride was added dropwise to the mixture while cooling to 0 ° C., and the mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into ice water, the dichloromethane layer was washed successively with aqueous sodium hydrogen carbonate and brine, dried over Glauber's salt, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (developing solvent ethyl acetate: hexane = 1: 1) to quantitatively obtain 99 mg of oily compound (11). [Α] 20 D-36.2 ° (C = 1.1, chloroform)

【0026】参考例 11 化合物(12)の製造 化合物(11)127mg(0.442mM)にメターノ
ル14ml、2.5N水酸化カリウム水溶液14mlを加
え、アルゴン気流下12時間攪拌還流した。反応液を減
圧下溶媒留去し、酢酸エチルで3回抽出した。酢酸エチ
ル層を食塩水で洗浄し、芒硝で乾燥後、減圧濃縮して組
製の化合物101mgを得た。これは精製することなく次
の反応に使用する。
Reference Example 11 Preparation of Compound (12) To 127 mg (0.442 mM) of Compound (11) were added 14 ml of methanol and 14 ml of 2.5N potassium hydroxide aqueous solution, and the mixture was stirred and refluxed for 12 hours under an argon stream. The solvent of the reaction solution was evaporated under reduced pressure, and the mixture was extracted 3 times with ethyl acetate. The ethyl acetate layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give 101 mg of a compound compound. It is used in the next reaction without purification.

【0027】実施例 1 化合物(13)の製造 化合物(12)101mg(0.44mM)にブタノール
14ml、トリエチルアミン0.6ml(10倍モル)およ
び4,6−ジクロロ−5−アミノピリミジン181mg
(2.5倍モル)を加え、アルゴン気流下40時間攪拌
還流した。反応液を減圧下溶媒留去し、残渣をジクロロ
メタンで数回抽出した後、シリカゲルカラムクロマトグ
ラフイー(展開溶媒酢酸エチル:ヘキサン=1:1、次
いで4:1)により精製して化合物(13)116mg
(収率73%)を得た。 〔α〕19D−77.5°(C=1.06、クロロホル
ム) 原料(12)16mg回収した。
Example 1 Preparation of compound (13) 101 mg (0.44 mM) of compound (12) was mixed with 14 ml of butanol, 0.6 ml of triethylamine (10 times mol) and 181 mg of 4,6-dichloro-5-aminopyrimidine.
(2.5 times mole) was added, and the mixture was stirred and refluxed for 40 hours under an argon stream. The reaction solution was evaporated under reduced pressure, the residue was extracted several times with dichloromethane, and then purified by silica gel column chromatography (developing solvent ethyl acetate: hexane = 1: 1, then 4: 1) to give compound (13). 116 mg
(Yield 73%) was obtained. [Α] 19 D-77.5 ° (C = 1.06, chloroform) 16 mg of the raw material (12) was recovered.

【0028】実施例 2 化合物(14)の製造 化合物(13)116ml(0.325mM)をトリエチ
ルホルソホルメートおよび無水酢酸の当モルの混合物2
mlに溶かし、室温で2時間攪拌した。反応液を減圧下冷
時濃縮し、残渣を重曹水を含む氷に注ぎ、しばらく攪拌
した。これを酢酸エチルで抽出し、抽出液を水洗し、芒
硝で乾燥した後、減圧下溶媒留去して定量的に化合物
(14)を得た。この残渣は、精製することなく次の反
応に使用する。
Example 2 Preparation of compound (14) 116 ml (0.325 mM) of compound (13) was mixed with equimolar mixture of triethylformoformate and acetic anhydride 2
It was dissolved in ml and stirred at room temperature for 2 hours. The reaction mixture was concentrated under cooling under reduced pressure, the residue was poured into ice containing aqueous sodium hydrogen carbonate, and the mixture was stirred for a while. This was extracted with ethyl acetate, the extract was washed with water, dried over sodium sulfate, and the solvent was distilled off under reduced pressure to quantitatively obtain compound (14). This residue is used for the next reaction without purification.

【0029】実施例 3 化合物(15)の製造 実施例2で得た残渣119mg(0.325mM)を乾燥
テトラヒドロフランに溶かし、これに−78℃に冷却下
乾燥アンモニアガスを1時間吹き込んだ。次いで反応物
を封管し、40〜50℃で16時間加温した。反応後、
開封して減圧下溶媒留去し、次いで残渣をジクロロメタ
ンで数回抽出した。抽出液を水洗し、芒硝で乾燥した
後、減圧下溶媒留去した。残渣をシリカゲルカラムクロ
マトグラフイー(展開溶媒酢酸エチル:ヘキサン=1:
1、4:1、次いでジクロロメタン・メタノール=9
5:5)により精製して化合物(15)22mg(収率2
0%)を得た。 〔α〕20D−69.8°(C=1.1、クロロホルム)
Example 3 Production of Compound (15) 119 mg (0.325 mM) of the residue obtained in Example 2 was dissolved in dry tetrahydrofuran, and dry ammonia gas was blown into this while cooling to −78 ° C. for 1 hour. The reaction was then sealed and warmed at 40-50 ° C for 16 hours. After the reaction
The mixture was opened, the solvent was distilled off under reduced pressure, and the residue was extracted several times with dichloromethane. The extract was washed with water, dried over Glauber's salt, and the solvent was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography (developing solvent ethyl acetate: hexane = 1: 1).
1, 4: 1, then dichloromethane / methanol = 9
5: 5) and compound (15) 22 mg (yield 2
0%). [Α] 20 D-69.8 ° (C = 1.1, chloroform)

【0030】実施例 4 ネプラノシンA(16)の製
造 化合物(15)22mg(0.063mM)をメタノール
1mlおよび2N塩酸1mlの混合溶液に溶かし、室温で1
6時間攪拌した。反応液を減圧下メタノールを留去し、
残渣に水を加え、アンバーライトCG120(H+ )に
チャージして、0.5%アンモニア水で溶出した。溶出
液を減圧濃縮してネプラノシンA13.3mg(収率80
%)を得た。 〔α〕25D−148°(C=0.45、水) 融点:215〜217℃ 上記製品をメタノール:水=9:1により再結晶化して
再結品を得た。 〔α〕20D−152°(C=0.3、水) 融点:220〜222℃ このものの比旋光度および融点は醗酵法により得られる
ネプラノシンAの文献値と一致した。
Example 4 Production of nepranocin A (16) 22 mg (0.063 mM) of compound (15) was dissolved in a mixed solution of 1 ml of methanol and 1 ml of 2N hydrochloric acid, and the mixture was allowed to stand at room temperature for 1 hour.
Stir for 6 hours. The reaction solution was distilled under reduced pressure to remove methanol,
Water was added to the residue, Amberlite CG120 (H + ) was charged, and the residue was eluted with 0.5% aqueous ammonia. The eluate was concentrated under reduced pressure to obtain 13.3 mg of neplanocin A (yield 80
%) Was obtained. [Α] 25 D-148 ° (C = 0.45, water) Melting point: 215 to 217 ° C. The above product was recrystallized with methanol: water = 9: 1 to obtain a recrystallized product. [Α] 20 D-152 ° (C = 0.3, water) Melting point: 220-222 ° C. The specific optical rotation and the melting point of this substance were in agreement with the literature values of neplanocin A obtained by the fermentation method.

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 式 【化1】 (式中、R’2 およびR’3 は各々水酸基の保護基、
R’4 は水酸基の保護基を示す)で表されるシクロペン
テン化合物を5−アミノ−4,6−ジハロピリミジンを
反応させて式 【化2】 (式中、Xはハロゲン原子を示し、R’2 、R’3 およ
びR’4 は前記と同じ基を意味する)で表されるピリミ
ジン化合物を得、該化合物をイミダゾール閉環して式 【化3】 (式中、R’2 、R’3 、R’4 およびXは前記と同じ
基を意味する)で表されるプリン化合物を得、該化合物
の6位のハロゲノ基をアミノ基に変換し、次いで2’
位、3’位および6位の水酸基の保護基を脱離すること
を特徴とするネプラノシンAの製造法。
1. The formula: (In the formula, R ′ 2 and R ′ 3 are each a hydroxyl-protecting group,
R '4 is a cyclopentene compound represented by a protecting group for hydroxyl group) by reacting 5-amino-4,6-dihalopyrimidine formula ## STR2 ## (Wherein, X represents a halogen atom, and R ′ 2 , R ′ 3 and R ′ 4 mean the same groups as described above), and the compound is ring-closed with an imidazole to give a pyrimidine compound represented by the formula: 3] (Wherein, R '2, R' 3 , R '4 and X mean the same groups as above) to give purine compound represented by converting the 6-position of the halogeno group of the compound to the amino group, Then 2 '
A method for producing neplanocin A, which comprises removing the protective groups for the hydroxyl groups at the 3'-position and the 6-position.
【請求項2】 シクロペンテン化合物が光学活性体であ
ることを特徴とする請求項1記載の製造法。
2. The method according to claim 1, wherein the cyclopentene compound is an optically active substance.
【請求項3】 光学活性体が(−)−異性体であること
を特徴とする請求項2記載の製造法。
3. The method according to claim 2, wherein the optically active substance is a (−)-isomer.
【請求項4】 R’2 がR’3 と共にイソプロピリデン
基であり、R’4 がメトキシメチレン基であることを特
徴とする請求項1記載の製造法。
4. The method according to claim 1, wherein R ′ 2 together with R ′ 3 is an isopropylidene group, and R ′ 4 is a methoxymethylene group.
JP2414449A 1990-12-25 1990-12-25 New process for producing neplanocin a Pending JPH0592974A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2414449A JPH0592974A (en) 1990-12-25 1990-12-25 New process for producing neplanocin a

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2414449A JPH0592974A (en) 1990-12-25 1990-12-25 New process for producing neplanocin a

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP57090145A Division JPS58206570A (en) 1982-05-26 1982-05-26 Novel method for preparing neplanocin a and intermediate therefor

Publications (1)

Publication Number Publication Date
JPH0592974A true JPH0592974A (en) 1993-04-16

Family

ID=18522927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2414449A Pending JPH0592974A (en) 1990-12-25 1990-12-25 New process for producing neplanocin a

Country Status (1)

Country Link
JP (1) JPH0592974A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008266334A (en) * 1998-05-25 2008-11-06 Chisso Corp New process for producing neplanocin a and intermediate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008266334A (en) * 1998-05-25 2008-11-06 Chisso Corp New process for producing neplanocin a and intermediate

Similar Documents

Publication Publication Date Title
RU2360919C2 (en) Method of obtaining 2'-desoxy-2', 2'-difluorocytidine
AU2008327061B2 (en) Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein
US4973674A (en) Chiral synthesis of anthracyclines from substituted anthraquinones
JP3453188B2 (en) Method for producing oleanolic acid derivative
Marlier et al. A highly efficient chemical synthesis of Rp and Sp adenyl (3′-5′) adenyl-o, o-phosphorothioate
EP0638586A2 (en) Nucleoside derivatives and methods for producing them
JPH0592974A (en) New process for producing neplanocin a
JPS5821692A (en) Novel aminoglycoside
Barton et al. Reactions of relevance to the chemistry of aminoglycoside antibiotics. Part 15. The selective modification of neamine by radical-induced deamination
JP2648472B2 (en) β-lactam compound and method for producing the same
Katagiri et al. Synthesis and biological evaluation of 9-(f-2, c-3-bishydroxymethyl-r-cyclopropylmethyl)-9H-adenine (a lower methylene homolog of carbocyclic oxetanocin) and related compounds
US4774327A (en) N-glycolylneuraminic acid derivative
JPS62292793A (en) Novel anthracycline
JPS58206570A (en) Novel method for preparing neplanocin a and intermediate therefor
JP2000226397A (en) Lipid a intermediate, its production and production of lipid a and its derivative
US4992368A (en) Novel process for producing oxetanocin G
US20090281301A1 (en) Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate
JP2625620B2 (en) Fucosyl-glucosamine derivatives
JP3242472B2 (en) Novel cancer cell metastasis inhibitor 6- (trifluoroacetamide) -4,5-dihydroxypiperidine-3-carboxylic acid and method for producing the same
JPH0429669B2 (en)
SU1397455A1 (en) Method of producing (2ъ-5ъ)- and (3ъ-5ъ)-diadenozinmonophosphates
WO1997042194A1 (en) Process for the preparation of an indacene compound
JPH0631303B2 (en) Novel 6-Substituted Aldohexopyranos Derivative
JPH01132585A (en) Dc-52 derivative
JPS631949B2 (en)